118
Participants
Start Date
August 3, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
Sugammadex
Sugammadex will be used to reverse rocuronium neuromuscular blockade (NMB). Dose will be according to participant actual body weight.
Neostigmine
Neostigmine will be used to reverse rocuronium NMB. Dose will be according to participant actual body weight.
Glycopyrrolate
Glycopyrrolate will be co-administered with neostigmine during reversal of rocuronium NMB. Dose will be according to participant actual body weight.
Rocuronium
To achieve NMB, participants will receive the steroidal neuromuscular blocking agent Rocuronium Bromide administered via IV infusion and dosed according to participant actual body weight. It will be used per label to maintain muscle relaxation as an adjunct to general anesthesia.
University Hospital, Columbia
Merck Sharp & Dohme LLC
INDUSTRY
University of Missouri-Columbia
OTHER